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Abstract 
Overdose related to prescription opioids have reached an epidemic level in the US, creating an 
unprecedented national crisis. This has been exacerbated partly due to the lack of tools for physicians to 
help predict the risk of whether a patient will develop opioid use disorder. Little is known about how 
machine learning can be applied to a big-data platform to ensure an informed, sustained and judicious 
prescribing of opioids, in particular for commercially insured population. This study explores 
Massachusetts All Payer Claims Data, a de-identified healthcare dataset, and proposes a machine learning 
framework to examine how naïve users develop opioid use disorder. We perform several feature selections 
techniques to identify influential demographic and clinical features associated with opioid use disorder from 
a class imbalanced analytic sample. We then compare the predictive power of four well-known machine 
learning algorithms: Logistic Regression, Random Forest, Decision Tree, and Gradient Boosting to predict 
the risk of opioid use disorder. The study results show that the Random Forest model outperforms the other 
three algorithms while determining the features, some of which are consistent with prior clinical findings. 
Moreover, alongside the higher predictive accuracy, the proposed framework is capable of extracting some 
risk factors that will add significant knowledge to what is already known in the extant literature. We 
anticipate that this study will help healthcare practitioners improve the current prescribing practice of 
opioids and contribute to curb the increasing rate of opioid addiction and overdose.  
Keywords: Opioid use disorder, Opioid addiction epidemic, Risk prediction, Big data analytics, Machine 
learning, Predictive analytics. 
1. Introduction 
According to Center for Disease Control and Prevention (CDC), the opioid overdose epidemic—a national 
public health emergency—takes an average of 130 lives in the US every day (CDC, 2017a), more than 35% 
of which are attributable to the overdose of legally obtained prescription opioids (CDC, 2017b). Opioids 
were responsible for approximately 47,736 deaths in 2017, and opioid overdose deaths (deaths involved 
prescription and illegal opioids) were six times higher in 2017 than 1999 (CDC, 2017a), the largest increase 
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in overdose-related deaths in this country’s history. This statistic is difficult to fully grasp—shocking in its 
scope and overwhelming in the utter complexity of trying to curtail the overflow of legal and illicit drugs 
that have created this national crisis. Although strong evidence for long-term benefits of opioid therapy for 
chronic pain management is still lacking (Chapman et al., 2010), almost 58 opioid prescriptions were 
written for every 100 Americans with an average of 3.4 opioid prescriptions issued per patient (CDC, 2019).  
Lack of stringent restrictions on the flow of prescription opioids increases the risk of developing 
opioid use disorder without a prescription due to the high abuse potential for opioids and risk of diversions 
(CDC, 2014). A key challenge for handling opioid crisis is  the difficulty in predicting whether a patient is 
likely to become addicted to opioids. Currently, when prescribing opioids, physicians often use risk 
assessment tests based on a brief risk interview. However, prior study has shown that the Opioid Risk Tool 
(ORT) and Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) inadequately 
predict which patients will be misusing opioid medications (Jones & Moore, 2013). Thus, opioids are being 
prescribed at an alarming rate and current risk prediction methods are apparently inefficient, a duo which 
forces the whole nation to embrace a pressing epidemic of addiction and overdose. Opioid-overdose related 
fatalities could be prevented if better risk assessing methods to ensure an informed opioid prescribing 
practice could be developed.  
However, there has been little in-depth research on predicting the risk of developing opioid use 
disorder beforehand to help physicians prescribe them in an informed way. Several prior research only used 
regression based techniques to examine the association of risk factors with opioid use disorder (opioid 
abuse, misuse and/or dependence)  (Ciesielski et al., 2016; Dufour et al., 2014; Edlund et al., 2010; Ives et 
al., 2006; Rice et al., 2012; Skala et al., 2013; Thornton et al., 2018; Turk, Swanson, & Gatchel, 2008; 
White, Birnbaum, Schiller, Tang, & Katz, 2009) and overdose (Glanz et al., 2018). Patients’ demographics 
(e.g., age, ethnicity, geographic regions) (Cepeda, Fife, Chow, Mastrogiovanni, & Henderson, 2013), prior 
clinical history of mental illness (Rice et al., 2012; Skala et al., 2013), non-opioid substance use disorder 
(Rice et al., 2012), tobacco abuse (Skala et al., 2013), and non-dependent alcohol abuse (McCabe, Cranford, 
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& Boyd, 2006; Rice et al., 2012; Skala et al., 2013) were considered as potential risk indicators for opioid 
use disorder. Research conducted in (Brummett et al., 2017; Liang, Goros, & Turner, 2016) used logistic 
regression and found that substance abuse was the greatest predictor of opioid overdose for both male and 
female. However, the higher odds ratio related to male indicated stronger association between opioid 
overdose and male patients. These results were reaffirmed by other studies (Ciesielski et al., 2016; Rice et 
al., 2012) using logistic regression techniques, concluding that males were more likely to experience opioid 
use disorder. Another study (Thornton et al., 2018) applied logistic regression and found that the initial 
opioid regimen is a strong predictor of chronic opioid therapy. A cox regression model (Glanz et al., 2018) 
was able to distinguish high-risk and low-risk patients for naloxone prescriptions with a predictive accuracy 
of 66-82%. Therefore, prior research (Brummett et al., 2017; Ciesielski et al., 2016; Glanz et al., 2018; 
Hylan et al., 2015; Liang et al., 2016; Rice et al., 2012; Thornton et al., 2018) commonly used multi-variate 
logistic regression and cox regression models that achieved sub-optimal predictive performance. Besides, 
the reported predictive accuracy may also suffer from biased estimation as no oversampling methods were 
adopted to take care of the class imbalanced issue (i.e. the number of patients with opioid use disorder is 
significantly smaller than the patients without opioid use disorder), which potentially limit the reliability 
and applicability of those models to predict opioid use disorder and overdose (Chawla, Bowyer, Hall, & 
Kegelmeyer, 2002; Japkowicz, 2000).  
Several prior studies utilized data mining and machine learning techniques that perform with higher 
accuracy while predicting outcomes in a variety of healthcare applications (Islam, Hasan, Wang, Germack, 
& Alam, 2018). Such studies include but are not limited to predicting mortality of intensive care unit (ICU) 
patients (Le et al., 1984; Luo, Xin, Joshi, Celi, & Szolovits, 2016; Pirracchio et al., 2015; Poole et al., 2012; 
Rosenberg, 2002), sepsis related organ failure assessments (Gultepe et al., 2013; Ribas et al., 2011; 
Simpson, 2016), breast cancer survivability (Delen, Walker, & Kadam, 2005), risk of 30-day hospital 
readmission for patients with heart failure, pneumonia, serious mental illness (SMI) (Chin, Liu, & Roy, 
2016; Kansagara et al., 2011), generating treatment plan for diseases such as ulcers (Cho, Park, Kim, Lee, 
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& Bates, 2013), and depressions (Klein & Modena, 2013). However, research leveraging advanced big data 
analytics to precisely and proactively predict the risk of developing opioid use disorder is still in its infancy. 
Only a few studies used machine learning models in predicting opioid dependency (Ellis, Wang, Genes, & 
Ma’ayan, 2019), overdose (Lo-Ciganic et al., 2019), detecting misuse by utilizing emergency medicine 
service (EMS) data (Prieto et al., 2020) and opioid cessation (Cox et al., 2019). However, research 
performed in (Lo-Ciganic et al., 2019) using claims data only considered individuals with age above 65 
(Medicare beneficiaries), while Ellis et al. (2019) utilized lab tests and vital signs from electronic health 
record (EHR) data and only implemented a single classifier—Random Forest. Cox et al. (2019) only 
included 6,188 African Americans and 6,835 European Americans, leading to a narrowly defined study 
cohort.  
Therefore, after reviewing the extant literature on the applicability of machine learning and multi-
variate regression based techniques to predict risk of opioid use disorder and overdose, we identified the 
following limitations of previous research: (1) smaller sample sizes that did not support robust analytical 
files, (2) a narrow set of pre-selected clinical and socio-demographic factors for inclusion in the predictive 
model, (3) only multi-variate logistic regression and cox regression based predictive analytics were used, 
which only examined the associations between risk factors and opioid used disorder and/or overdose, and 
(4) reported low predictive accuracy, which reduces the reliability and applicability of existing models to 
predict opioid use disorder. These limitations of the existing studies create an avenue for further research 
to deploy data mining and machine learning techniques on large-scale healthcare claims dataset to predict 
opioid use disorder, and to investigate their predictive power. Hence, this study intends to provide the 
knowledge and tools necessary for improving opioid-prescribing practice and help curb the country’s 
rapidly increasing rate of opioid addiction. The essential idea is to harness the potential of big-data analytics 
to identify patient-level factors associated with opioid use disorder, and subsequently develop a model to 
predict the likelihood of developing such opioid use disorder with higher accuracy. We anticipate that big-
data analytics can potentially transform information into knowledge about how a naïve opioid patient 
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progresses towards opioid use disorder, potentially supporting the development of future interventional 
strategies to prevent subsequent drug overdose. The results of our investigation will help physicians predict 
the risk of a patient to develop opioid use disorder at a later stage after being prescribed opioids. 
The key contributions of this study are:  
1. We develop a big data analytics framework that can analyze large-scale healthcare claims datasets in an 
effort to investigate patients’ long-term opioid usage pattern. The proposed framework reveals how an 
opioid naïve patient may develop opioid use disorder at a later stage after an initial opioid prescription, 
and determines the influential features that are significant predictors of such opioid use disorder. Because 
there is a paucity of structured datasets populated with influential risk factors of opioid use disorder, the 
development of a reliable predictive model has been a challenging task. However, with our study, we 
show that the use of predictive analytics to inform judicious opioid prescribing practice is feasible with 
administrative claims datasets that provide information regarding patients’ clinical characteristics. We 
successfully leverage several feature selections and a class balancing technique, supported by a large 
number of  commercially insured population to develop a framework that has not been proposed yet to 
address opioid use disorder.  
2. Unlike existing studies which either focused on specific subgroups of population such as Medicare 
individuals with age above 65 (Lo-Ciganic et al., 2019), African Americans and European Americans 
(Cox et al., 2019), or used a single tree-based classifier (Ellis et al., 2019), this study includes 
commercially insured population with age under and above 65 years in the analytic sample and 
implements a set of machine learning models to predict opioid use disorder. We demonstrate that, apart 
from Logistic Regression, other machine learning algorithms superiorly predict the likelihood of opioid 
use disorder using a large analytic sample that is class imbalanced, and entails skewness and sparsity of 
features. Furthermore, our study achieved superior predictive performance as compared to existing study. 
Along with higher predictive power we identify risk factors, which are significant predictors of opioid 
use disorder, and will add knowledge to the existing literature.  
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The rest of the paper is organized as follows: Section 2 presents the materials and methods used, 
Section 3 demonstrates the results and provides a discussion of the findings. Finally, Section 4 concludes 
with a summary of the work conducted in this study along with some limitations and future research 
directions.  
2. Materials and Methods 
2.1. Data Source 
We use the Massachusetts All Payer Claim Datasets (MA APCD)(CHIA) which we currently house at the 
Northeastern Center for Health Policy and Healthcare Research, and is overseen by the Center for Health 
Information and Analysis (CHIA). This unique database includes all medical claims, pharmacy claims, and 
member eligibility information associated with commercial insurance claims in Massachusetts between 
2011 and 2015. The dataset provides unique identifiers for all patients and types of providers (e.g., 
hospitals, physicians, nursing homes, rehabilitation facilities) that can be used to link claims for individuals 
across files. The pharmacy claims file contains data for approximately 470 million prescriptions and the 
medical claims file has approximately 1.63 billion claims for Massachusetts residents. The pharmacy claim 
file contains information on each prescription claim including the type of medication, the dosage, and the 
days’ supply. The medical claim file includes information pertaining to a patient’s clinical condition 
including principal diagnosis recorded as ICD-9 codes and ICD-10 codes for claims after October 1, 2015, 
services and procedures received, and payment (i.e., how much the provider received from the health plan 
for the services provided). Both the pharmacy and medical claims files can be linked to the member 
eligibility file that contains information on age, gender, insurance status (e.g., name and type of plan 
including co-pays and deductible).  
 
2.2. Proposed Framework for Predicting Opioid Use Disorder Using Big-data Analytics 
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As previously mentioned, there is over prescriptions of opioids for acute and chronic pain management that 
can result in an increased risk of addiction and overdose (Fishbain, Cole, Lewis, Rosomoff, & Rosomoff, 
2007). Along with the potency and duration of prescribed dosage there are also other factors entailing a 
patient’s clinical history such as socio-economic and demographic characteristics, which together 
potentially lead an opioid naïve patient towards the increased risk of developing opioid use disorder. Given 
variation in patients’ characteristics, there might be different paths that underline a patient’s tendency or 
likelihood of developing opioid use disorder at a later stage after they have initiated opioid prescriptions. 
We investigate such paths as constituting distinctive patient-level characteristics. Identifying the influential 
factors associated with patients who at some point abuse these drugs is critical to determine the risk of 
future incidence of opioid use disorder. We hypothesized that there exists similarity in these factors for 
patients with opioid use disorder. Thus, our proposed framework starts with determining the influential 
features associated with opioid use disorder followed by the implementation and validation of  machine 
learning algorithms as depicted in Figure 1 and Figure 2, respectively. 
[Figure 1 near here] 
[Figure 2 near here] 
The features in the analytic file are ascertained before an opioid naïve patient develops or shows any 
sign of opioid use disorder in the follow up time period. Opioid naïve patients are identified from the 
pharmacy claims dataset. These are the patients who filed at least one claim that was identified as an opioid-
related claim (identified using national drug codes) and had no other opioid prescriptions one year prior to 
the index date. The index date is chosen as the most recent fill date of an opioid prescription during the 
study time frame. Consistent with the prior studies (Ciesielski et al., 2016; Rice et al., 2012; White et al., 
2009), for each opioid naïve patient, we take the first opioid prescription and from the date of that 
prescription we track the patient from 6 to 12 months further in time in the medical claims dataset to 
determine whether they had developed any sort of opioid use disorder. In order to identify such incidence 
of opioid use disorder, we used ICD-9 diagnosis codes associated with dependence and abuse of opioids 
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and other drugs including heroin and methadone (see Table 5 in Appendix for corresponding clinical 
diagnosis and  associated ICD-9 codes). If an opioid naïve patient is diagnosed with any of those ICD-9 
codes, we consider that patient as identified with opioid use disorder and without opioid use disorder 
otherwise. The first 6 months since the index prescription are used to collect information about the clinical 
diagnosis and opioid usage-pattern that had taken place once an opioid-naïve patient initiated opioid 
prescription. We use the term OUD to refer to patients with opioid use disorder and NOUD for patients 
without opioid use disorder. For both OUD and NOUD patients, we go one year back in time and gather 
their clinical history. Tracking of patients is censored when any incidence of opioid use disorder is identified 
within the follow up period. The outline of this conceptual framework is presented in Figure 3. 
[Figure 3 near here] 
2.3. Data Pre-processing, Feature Elimination and Implementation of predictive Model 
Given that the success of a prediction model depends on how the features are being presented, we transform 
the raw MA APCD into influential features. MA APCD is a claim-level dataset with each record 
representing a unique medical or pharmacy claim associated with one patient. This also means that one 
patient can have multiple claims. This structure of dataset is not suitable for training machine learning 
models since it requires a patient-level instead of a claim-level dataset. Therefore, we aggregate claim-level 
information into patient-level information to make the dataset suitable for training and testing machine 
learning models. This includes capturing patient’s demographic as well as clinical history as an independent 
feature of the dataset that may or may not have significant association with opioid use disorder.  
This process entails following steps. The outline of these steps is presented in Figure 4, and the details are 
given in the following subsections.  
 
 
2.3.1. Dealing with Missing Values and Feature Engineering 
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Age (categorical): Age for approximately 0.72% patients without opioid use disorder were missing, which 
we impute with mean age of all other patients without opioid use disorder (after considering overall age 
distribution). We consider age as categorical feature instead of a continuous one. Age is divided into five 
different buckets: i) 18-25, ii) 26-35, iii) 36-55, iv) 56-64, and v) above 65 in an effort to understand whether 
or not a patient belonging to a certain age-bin is more likely to develop opioid use disorder than other.   
Gender (categorical): Approximately 0.02% records had gender values either missing or ‘unknown’. 
The distribution of remaining data for male/female is approximately 43:57, so instead of imputing missing 
or unknown values as either male or female, we remove those records. 
Degree of chronicity (categorical) of opioid usage: We engineer this feature to define the chronicity of 
opioid usage of opioid-naïve users. We use Proportion of Days Covered (PDC) to determine such chronicity 
of opioid-usage. PDC is defined as the fraction of days a patient was on opioid medications within one year 
since their first opioid prescription. We then categorize the PDC value into four levels. Patients with a PDC 
less than 20% are defined as non-chronic, whereas those with a PDC value greater than 80% are defined as 
highly chronic users of opioids. A PDC value within the range of 20% to 49%, and 50% to 79% are 
attributed to less chronic and moderately chronic users, respectively. 
ICD-codes (categorical): In the data, the primary diagnoses were recorded as standard ICD-codes 
(which are alpha-numeric characters). As these ICD codes are difficult to interpret in their original form, 
we replace ICD-codes with their actual descriptions to make the data and results more interpretable. 
[Figure 4 near here] 
2.3.2. Eliminating Features with Low Variance 
The final analytic file comprises approximately 600,000 patients and 12,000 features. Apart from age, sex, 
and zip code, all other features entail patients’ clinical history extracted as ICD-9 codes. If a patient is 
diagnosed with a particular ICD-9 code, then we record that as n or 0 (where n is the number of times that 
patient is diagnosed for that particular ICD-9 code). This dimension comprising 600,000 patients and 
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12,000 features made further analysis difficult, so we eliminate less important features. When an analytic 
sample entails a large number of features (i.e., high dimensional), the training time for the model grows 
exponentially, and the risk of model overfitting also increases with number of features. The feature selection 
methods such as the one like Variance Threshold (VT) helps address these issues by reducing the number 
of features without losing much of the total information. Without training any model, we are required to 
eliminate features, so we chose the variance threshold (VT) method, which removes features with low 
variance. This algorithm only looks at the features (or predictors) and not the outcomes (or target). So, it is 
similar to an unsupervised machine learning technique. It removes features that have the same value for all 
the records in the sample. By having multiple features in the dataset, we expect to capture certain variance 
in the data that can help us in predicting the outcome. We use the VT method to calculate the variance of 
each feature and then only retained features with variance higher than the pre-defined threshold. Before 
adjusting a threshold for VT, we examine the distribution of variances of all the features and pick a threshold 
equal to 0.03 that covers most of the features, which capture some level of variance in the dataset. Meaning, 
if variance of a feature is close to 0, it is expected that most of its values are very close to each other (or 
same) and it does not help in distinguishing one patient from the other, thus does not contribute significantly 
when we predict opioid use disorder. There exists some general guidelines as per scikit-learn’s 
documentation (scikit_learn, 2019): Suppose that we have a dataset with Boolean features and we want to 
remove all features that are either one or zero (on or off) in more than 80% of the samples. Boolean features 
are Bernoulli random variables, and the variance of such variables is given by	𝑉𝑎𝑟(𝑥) = 𝑝(1 − 𝑝).  
2.3.3. Retaining Most Important Features 
After VT, we had 3076 features with a variance	≥ 0.03. Our goal is to make the models more interpretable 
and computationally more efficient. Therefore, we also implement Chi2 test, following VT, to retain only 
those features that are statistically significant with respect to target (i.e., opioid use disorder). A two tailed 
statistical significance test with a p-value set at < 0.05 is performed, reducing to 2628 features, which are 
used to train the predictive models. 
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To further reduce the number of features and improve models’ interpretability, we use recursive feature 
elimination (RFE) technique, which removes (or eliminates) features recursively by pruning the original 
set of features from the model. The RFE takes a model trained with all the available features and assigns 
weights to whole set of features (either as coefficients for linear model or feature importance for tree-based 
model). In each iteration, the least important features are pruned based on weights. By doing this, it achieves 
the goal of getting a smaller set of features in each iteration and eventually ending up with only those  
features that have the most predictive power. As such, we are required to decide how many features we 
want to prune at the end of each iteration and provide a stopping condition for the RFE to terminate in order 
to get a feasible result. Using cross-validation technique, we set to remove 10% of the features after each 
iteration. The reason behind choosing 10% as the fraction of features to be removed after each iteration is 
to reduce the computational burden while still performing as many iterations as feasible. To develop a 
clinically interpretable model, we need to determine the set of features, which can provide higher area under 
receiving operating characteristics curve (AUC) and eliminate redundant features from the model. Reducing 
number of features (i.e., from 2628) by recursively training four different models and investigating their 
predictive performance on the test data was computationally expensive. Therefore, in every iteration, we 
have chosen 10% of the remaining features to be eliminated from the analytic sample. However, this 10% 
can be considered as a sensitivity-parameter of our framework which can be tuned to assess its impact. In 
order to set a stopping conditionfor RFE, we further investigate the change in AUC value by reducing the 
number of features from 2628, and determine the number of features that provide the maximum AUC values 
for different predictive models. 
Another subtle consideration with RFE is that if we use it for different types of models such as Logistic 
Regression, Decision Tree, Random Forest etc., then it produces (or retains) different sets of features for 
different models when the algorithm terminates. For example, if we want to retain 50 features and we use 
RFE with logistic regression and random forest, we may end up with two different sets of 50 features from 
these two models. That is, these 50 features may or may not be same for two different models. 
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2.3.4. Handling Class Imbalance Data 
In the study sample, the prevalence of patients identified with opioid use disorder is approximately 1%, 
which represent a class imbalanced sample. Therefore, selection of an appropriate performance metric is 
critical to evaluate the models’ performance. To achieve better results, we implement Synthetic Minority 
Oversampling Technique (SMOTE)—a technique to over-sample a minority class (OUD patients). The 
SMOTE generate ‘synthetic’ samples of a minority class (OUD patients), resulting a similar distribution 
of NOUD and OUD patients in the dataset.  
2.4. Implementation of Machine Learning Algorithms to Facilitate the Proposed Risk Prediction Model 
We investigate and evaluate the performance of several well-known machine learning algorithms to 
precisely classify the individuals at risk for opioid use disorder. We frame this problem as a binary 
classification problem (i.e., target-variable is: ‘0’ if patient is identified with opioid use disorder and ‘1’ if 
identified without opioid use disorder). As we did not have labeled data, i.e., we did not have a target-
variable that would tell us if a person had opioid use disorder, we were required to infer the labels using 
clinical history associated with opioid-dependence, abuse or overdose from the medical claims file. 
Looking into the final analytic file, we observed big sparse features along with high-dimensional and 
non-linear feature space that may cause Logistic Regression based traditional classifiers to fail in terms of 
learning features or overfitting issues. We intend to adopt multiple predictive modeling approaches to 
present an analytic pipeline for predicting risk of opioid use disorder. More specifically, we intend to assess 
the performance of traditional Logistic Regression technique and also tree-based classifiers (Decision Tree, 
Random Forest, and Gradient Boosting).  
At first, we split the analytic file into train-test set (70/30 split). As the dataset is highly imbalanced 
(i.e., prevalence of OUD class is ~1%), we perform SMOTE to balance the training data and get a 50/50 
distribution of NOUD and OUD class. As a next step, we train different models as mentioned before. After 
training each model on an entire training dataset, we evaluate performance on both train and test data by 
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using precision, recall, F1-score, and AUC value. We further eliminate features via RFE technique as 
discussed before and end up with different set of features for different models that contain the most amount 
of predictive power. Finally, we train the model again with remaining most important features and evaluate 
performance as explained earlier. 
3. Results and Discussions 
The study sample consists of 44.51% male, of which 2.25% are identified with some aspects of opioid use 
disorder. The rest of the patients (55.49%) are female, and among them 0.81% had at least on diagnosis 
attributed to opioid use disorder. Out of approximately 66% of total patients with age above 36, a significant 
proportion (35.61%) had age in between 36 and 55, whereas only 18.21% and 12.2% had age within 56 to 
65 and above 65, respectively. The proportion of patients with age below 36 is approximately 33%, among 
them 11.75% had age within 18 to 25 and 15.28% were with age 26 to 35. Relatively, a small proportion 
of patients (6.94%) were found with age less than 18 in the study sample. The majority of the study sample 
with opioid use disorder had age in between 18 to 35, whereas a relatively lower number of patients with 
opioid use disorder are identified in the age group 36 to 55. Such proportions of patients with diagnosed 
opioid use disorder were much less for patients with age below 18 and above 55. 
3.1. Machine Learning Approaches and Comparison of Predictive Performance 
As mentioned in the previous section, the prevalence of patients with opioid use disorder is only ~1%.  
Therefore, accuracy alone cannot be considered as a reliable performance measure and choosing an 
appropriate evaluation metric is critical for selecting the best predictive model. As such, for each model, 
we determined precision, recall, F1-score and AUC, which is presented in Table 1 and Table 2, and 
graphical comparison is shown in Appendix (Figure 9 and Figure 10). We chose recall and AUC 
considering the following two reasons:  
i. We want to identify as many patients with opioid use disorder as we can. Identifying an OUD 
patient is more critical than misclassifying an NOUD patient, because if an OUD patient is 
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misclassified, then it is likely that this patient will go without proper medication management and 
become dependent on opioids, potentially leading to the increased risk of drug overdose. On the 
other hand, if we misclassify a NOUD patient as an OUD patient then at most the medical 
practitioner will be more careful and may end up with prescribing pain medicine with lower dosage 
and for short duration of time, which will likely to be even less addictive. Although such NOUD 
patients are at relatively less elevated risk of developing opioid use disorder, due to the 
misclassification as OUD, the prescriber will have to closely monitor those patients to properly 
taper the dosage and reduce the harms of opioid withdrawal symptoms. Additionally, the prescriber 
will also need to be aware of the physical dependence on opioids, which is different from addiction 
and can result even when a patient properly takes them as prescribed.  
ii. AUC is an effective  indicator of model’s ability to distinguish a rare class from the prevalent one. 
Based on these two performance measures, we present a comparative analysis across all four 
predictive models. Figure 7 shows the area under the receiving operating characteristic (ROC) curves for 
all four models. The value of this metric varies between 0 and 1, and the higher the values the better the 
model’s performance. In other words, we expect the curve to reach top-left corner and thus have a value 
close to 1. The AUC in case of test data are highest for Random Forest and Gradient Boosting for any value 
of false positive and true positive rates, and it is slightly lower for Decision Tree model. It is clear that the 
AUCs for tree-based models significantly outperform the AUC of the Logistic Regression model.  
[Table 1 near here] 
[Table 2 near here] 
After performing VT and chi-squared test on training sample, the recall value while predicting OUD 
patients for Logistic Regression, Decision Tree, Random Forest, and Gradient Boosting were 0.95, 0.99, 
0.99, and 1.0, respectively (Table 1). And, the AUC value in above-mentioned order of four algorithms 
were 0.965, 0.989, 0.985, and 0.994, respectively (Table 1). However, the performance of these models is 
not equally well in case of test sample; both recall, and AUC dropped significantly, apparently indicating 
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models’ overfitting issue. Then, while eliminating redundant features using RFE, with 49 features Random 
Forest model achieved an AUC value of 0.990 and 0.970 for training and test set, respectively as presented 
in Figure 5. The results from similar analyses for Gradient Boosting, Decision Tree, and Logistic 
Regression model are provided in Figure 13, Figure 14, and Figure 15, respectively as presented in 
Appendix. Both the Gradient Boosting and Logistic Regression models achieved maximum AUC value 
with 49 Features, while Maximum AUC for Decision Tree model was observed with 13 features.  
[Figure 5 near here] 
Moreover, after RFE, the recall of Random Forest model in predicting OUD also significantly improved to 
0.97, which is higher than 0.88 as found after VT and chi-squared test in case of test sample. Such recall of 
Random Forest model is also higher than what observed for Decision Tree (recall 0.92), Gradient-Boosting 
(recall 0.92), and Logistic Regression (recall 0.93) after RFE in case of test set. Besides, in terms of AUC, 
Random Forest model (AUC = 0.970) outperformed Decision Tree (AUC = 0.956), Gradient-Boosting 
(AUC = 0.956), and Logistic Regression (AUC = 0.935) as evident in Table 2 and Figure 7. Figure 6 
presents the comparison of model’s recall after VT in combination with Chi-squared test, and RFE.  
[Figure 6 near here] 
[Figure 7 near here] 
We further use Chi-square statistic to rank the final models (after RFE) based on features’ p-values 
from Chi2 test. Since the most important features for each model are retained after RFE, all of those features 
are statistically significant based on Chi-squared test (i.e., p-value < 0.05). We, then calculate the average 
of p-values for all the features in each model and find that Random Forest and Gradient Boosting models 
have almost same average p-values for their features. However, the same for Logistic Regression is turned 
out to be much higher, indicating the fact that the final feature set of Logistic Regression is less statistically 
significant than that of Random Forest and Gradient Boosting. Moreover, the average of p-values for all 
the features of Decision Tree is close to 0, indicating that the features are most statistically significant with 
respect to target. However, we have observed that the Random Forest model provides more accurate 
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predictions than Decision Tree in terms of AUC and recall. This could be because of the way the two models 
work. Since, it is important to accurately identify OUD patients, we still consider Random Forest as best 
model based on our analysis. 
Some meaningful insights from Logistic Regression model is obtained based on odds ratio (OR) 
associated with most important features. For this model, we consider female, age above 65, and non-chronic 
use of opioids as reference group for categorical variables with multiple levels. The top 10 features that 
have the highest 𝑂𝑅 are: moderate (13.66) and high chronic  use of opioids (12.25), poisoning by heroin 
(12.79), age 26 to 35 (11.27), age 18 to 25 (7.47),age 36 to 55 (4.13), male (1.81), poisoning by unspecified 
opium (alkaloids) (4.32) or opiates and narcotics (5.63), and less chronic use of opioids (4.14). Patients 
attributed to high chronic use of opioids are approximately 12.25 times more likely to develop opioid use 
disorder than did non-chronic use of opioids. Similar comparison can be made for patients with moderate 
and less chronic use of opioids. Compared to individuals with age above 65, patients aged in between 26 
and 35 are 11.27 times more likely to experience opioid use disorder. Similarly, male patients are 1.81 times 
more likely to have diagnosed with opioid use disorder than female. The rest of the top 10 features are 
discrete. 𝑂𝑅 for poisoning by heroin is 12.79, which means that if a patient is diagnosed once for poisoning 
by heroin, then he/she is approximately 12 times more likely to develop opioid use disorder as compared 
to patient who did not have diagnosed with heroin poisoning. 
From the feature importance plot of reduced Random Forest model (Figure 8), we see that along with 
previous diagnosis of opioid dependence, degree of chronicity, and age 26 to 35 are very important 
predictors of opioid use disorder. Such feature importance plots of Decision Tree and Gradient Boosting 
model are presented in Figure 11 and Figure 12 in Appendix. A brief clinical description of the top features 
obtained from all the four predictive models after RFE are presented in Table 3 (see Appendix) along with 
the corresponding ICD-9 codes. The important features in the Decision Tree model after RFE are somewhat 
similar to those we obtian from Random Forest model. In case of Gradient Boosting model, we see that this 
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model gives less importance to age-related features as compared to Random Forest and Logistic Regression 
models. 
[Figure 8 near here]   
3.2.  Discussion 
This study investigates the risk factors that lead an opioid naïve user towards the increased risk of opioid 
use disorder, and also leverage several machine leaning algorithms to predict the likelihood of such 
disorder. Unlike existing studies on predicting opioid dependency and abuse, we allow the selected 
predictive model to ascertain the risk factors associated with opioid use disorder rather than building a 
model using pre-selected features. Often times, it is argued that administrative claims datasets lack adequate 
clinical details for developing efficient and reliable predictive models for patient. However, our study 
demonstrates that such an approach is feasible and clinically significant in predicting potential opioid use 
disorder by extracting influential clinical factors using large-scale healthcare administrative claims data.      
Based on the comparison of several performance measures, our study shows that tree-based models, in 
general, outperform a Logistic Regression model, and among the tree-based models, Random Forest 
superiorly performs in predicting opioid use disorder with clinically significant features and higher 
predictive accuracy, potentially making this model applicable in clinical setting. The most important 
demographic features includes patients’ age between 18 to 25 and 26 to 35 , and male gender, a findings 
consistent with (Dufour et al., 2014), which reported increased risk of opioid use disorder for male patients. 
Among clinical factors, our model determined that prior history of opioid dependence, poisoning by heroin, 
opioid abuse, and prior evidences of drug withdrawal adverse effect related to mental illness or psychotic 
disorder, abuse of non-opioid drugs or substances, poisoning by unspecified drugs or medical substances, 
and dependence on unspecified alcoholic substance are strong predictors of opioid use disorder which 
supports several prior research (Edlund et al., 2010; Rice et al., 2012). Other clinical features entail previous 
history of dependence on unspecified drugs and (or) combinations of opioid type drugs with other drugs, 
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anxiety, depressive disorder, poisoning by opium (alkaloids), and long-term use of other medications add 
significantly valuable knowledge to what is already known regarding the risk factors of opioid use disorder.  
Because the prior history of opioid dependency has already been proven as a significant predictor of 
developing future dependence on opioid, it may be argued that inclusion of this feature may result in limited 
clinical significance of the predictive model. Towards a deeper investigation on this issue, we further train 
the Random Forest model excluding all the features that are related to any kind of prior history of opioid 
dependency and abuse. The reason behind considering the Random Forest model in this regard is its 
superiority over all other three predictive models. Results (presented in Table 4 in Appendix) demonstrate 
that exclusion of those features reduced the model AUC value to 0.833. In addition to that, we also observe 
a much lower value for model recall, implying that the model significantly failed to predict those OUD 
patients who actually had opioid use disorder. Therefore, such a predictive model will have a greater chance 
to potentially mislead the physicians, leading to enhanced risk for patients who are more likely to develop 
opioid use disorder.  
While several of our findings are noticeably consistent with prior clinical research examining the 
association of risk factors with different aspects of opioid use disorder (Dufour et al., 2014; Ives et al., 
2006; Rice et al., 2012; White et al., 2009), the predictive power of our analysis substantially adds value to 
the existing literature. Prior research also included the history of substance abuse (Ciesielski et al., 2016; 
Dufour et al., 2014; Glanz et al., 2018; White et al., 2009) and opioid abuse (Edlund et al., 2010; Rice et 
al., 2012) as predictors in the logistic regression model. However, those studies did not apply machine 
learning techniques and achieved suboptimal predictive performance as indicated by a lower value of c-
statistic (alternative measure of AUC) within a range of 0.75 to 0.92 (Ciesielski et al., 2016; Dufour et al., 
2014; Glanz et al., 2018; Rice et al., 2012; White et al., 2009). Moreover, the accuracy reported by c-statistic 
in the existing studies (Dufour et al., 2014; Rice et al., 2012; White et al., 2009) might also be overestimated 
given the fact that the dataset was highly imbalanced with a reasonably smaller proportion of total study 
sample of patients identified as opioid abusers or dependent. Such imbalance issue, if not overcome 
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properly could lead to an overfitted predictive model and biased estimation of accuracy value, which could 
potentially question the applicability and reliability of predictive model in such a highly critical application 
area. Our study, with the help of SMOTE takes care of this issue and achieves higher Recall and AUC 
value, which overcome the limitation of biased learning from imbalanced dataset.  
Although, one study (Lo-Ciganic et al., 2019) that used machine learning to predict risk of opioid 
overdose considered patients’ prior history of prescription opioid overdose, substance, and opioid use 
disorder and achieved a c-statistic of 0.90 for a Gradient Boosting model, it was limited within Medicare 
individuals aged above 65. Besides Logistic Regression technique, we also implement other tree-based 
algorithms and obtain an AUC value of 0.97. Because our analytic sample entails a large number of features 
with sparsity and skewness of features, it is perhaps not surprising that we found that tree-based models 
outperformed a Logistic Regression model in terms of AUC and recall value. As Logistic Regression 
belongs to a family of Generalized Linear Models (GLM), it can capture the linear relationship between 
predictors and outcomes, effectively. However, it is likely to fail in capturing some complex relationships. 
Because tree-based models are just structured hierarchy of rules to make predictions (not necessarily linear), 
they are robust to some above-mentioned data issues, and thus they outperform the Logistic Regression 
model.  As such, we suggest that researchers studying healthcare claims data to predict opioid use disorder 
could consider evaluating and implementing more than one classifier. Particularly, we recommend using 
the Random Forest model as it is evident from our analysis that the Random Forest model is able to identify 
OUD patients with higher accuracy as compared to a  Logistic Regression model while also efficiently 
determined the risk factors that are significant predictors of opioid use disorder. Hence, our investigation 
provides meaningful insights on risk factors associated with opioid use disorder along with a predictive 
decision support system with higher reliability that can be instrumental for healthcare practitioners.               
4. Conclusions, Limitations and Future Research Directions 
This study provides a machine learning framework that intends to serve as a decision support system for 
physicians at the point of care or initial opioid prescription to help identify the patients at risk of future 
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incidence of opioid use disorder. To the best of our knowledge, this is the first study utilizing MA APCD 
to develop a predictive analytics framework, particularly focusing on commercially insured prescription 
opioid users. While prior research largely dependent on the Logistic Regression based predictive technique 
suffered from overestimated accuracy due to imbalance data, our study tackles this issue utilizing SMOTE, 
and proposes a set of tree-based predictive models that achieved superior predictive performance over 
Logistic Regression model. We further utilize VT, Chi-squared test, and RFE techniques in an effort to 
enhance model computational efficiency and interpretability. Moreover, we are able to show that along 
with higher predictive performance, Random Forest model extracts the risk factors from patients’ one-year 
clinical history, some of those are consistent with prior findings of clinical literature. Thus, our study 
enables researchers and healthcare decision makers to utilize machine learning approach on healthcare 
claims datasets and provide with the ability to predict opioid use disorder.   
We note several limitations of our study. It was not possible to track patients’ clinical history before 
2011 due to the unavailability of the data. Because data were not available beyond 2015, we were not able 
to investigate how many of them were diagnosed with opioid overdose in the future. As such, we had to 
exclude years 2011 and 2015 from being considered as an index year.  In addition, we could not identify 
the patients with opioid use disorder in year 2014, as pursuant to federal policy, CHIA was required to 
remove all medical claims for drug dependence after 2013. Another limitation has to do with the selection 
of four (although well-known) out of the many other predictive algorithms. Besides, we have not 
implemented the predictive analytics framework in clinical setting, nor assessed the actual impact of such 
implementation on clinical decision, and we acknowledge that these are the issues with significant 
importance. However, we have successfully demonstrated that modern machine learning techniques can 
effectively and feasibly be used on large-scale healthcare claims datasets, particularly in predicting the risk 
of opioid use disorder for commercially insured individuals. Although SMOTE has reduced the bias caused 
by the majority class, it may perhaps result some overfitting. The synthetic observation created by SMOTE 
are usually sensitive to the specific samples of minority class that are selected form the true data distribution 
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as SMOTE utilizes k-nearest neighbors (KNN) to create synthetic observations. Because, the nature of the 
true data distribution (e.g., whether or not it is uniformly distributed) is not known and it is possible that 
the minority class samples (used to create synthetic observations) can be unlikely due to the presumable 
non-uniform true distribution of the data, then there are possibilities to fit the model to observations not 
truly representative of the original data distribution. This may perhaps introduce some degree of overfitting 
and lack of generalization ability of the predictive model. Despite this, because we used SMOTE on the 
training dataset and not on the entire dataset prior to cross validation, the model prediction was performed 
on the unseen data-fold in the first pass of cross validation, and similar process was followed for rest of the 
data-folds. Therefore, the above-mentioned overfitting due to SMOTE did not have substantial impact 
during the training phase of the models. 
Future study will extend implementing the current framework on claims dataset coming from other 
states that are highly afflicted with opioid overdose epidemic. The sensitivity of the proposed framework 
can also be investigated on other study sample including vulnerable population like Medicaid, and Veterans 
to reveal novel risk factors associated with the risk of opioid use disorder. Such analysis will also take into 
account other predictive algorithms to investigate and compare their predictive power with current findings. 
We also aim to develop a user interface so that physicians can utilize this as ready-to-use tool, which will 
generate a risk score for an individual before prescribing opioids once the required information associated 
with risk factors are provided.  
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Tables 
 
Table 3 
ICD codes of the clinical features obtained after RFE for four different models 
Features  Logistic 
Regression 
Decision 
Tree 
Gradient 
Boosting 
Random 
Forest 
ICD-9 
Codes 
History of poisoning by heroin ü ü ü ü 965.01 
History of poisoning by opium (alkaloids) ü ü ü ü 965.00 
Previous poisoning by other opiates and related narcotics ü    965.09 
Prior dependence (continuous) on other drugs in 
combinations with opioid ü 
 ü ü 304.71 
History of opioid abuse in remission ü ü ü  305.53 
Prior dependence (in remission) on other drugs in 
combinations with opioid ü 
   304.73 
Prior episodic dependence on opioid ü  ü ü 304.02 
Previous poisoning by unspecified drug or medicinal 
substance ü 
 ü ü 977.9 
History of unspecified opioid abuse ü ü ü ü 305.50 
History of episodic opioid abuse ü    305.52 
History of continuous opioid dependence ü ü ü ü 304.01 
History of unspecified opioid dependence ü ü ü ü 304.00 
Prior dependence on other specified drug ü    304.60 
Prior dependence (unspecified) on other drugs in 
combinations with opioid  ü ü ü ü 304.70 
Drug withdrawal ü  ü ü 292.0 
Prior dependence (episodic) on other drugs in combinations 
with opioid  ü 
   304.72 
History of opioid dependence in remission ü ü ü ü 304.03 
Prior history of continuous opioid abuse ü   ü 305.51 
Chronic or unspecified gastric ulcer with hemorrhage, 
without mention of obstruction ü 
   531.40 
Unspecified orthopedic aftercare ü    V54.9 
Other hemorrhagic disorder due to intrinsic circulating 
anticoagulants antibodies or inhibitors ü 
   286.59 
Malignant neoplasm of trigone of urinary bladder ü    188.0 
Lumbosacral root lesions not elsewhere classified ü    353.4 
Impaired glucose tolerance test (oral) ü    790.22 
acute myocardial infarction of unspecified site episode of 
care unspecified ü 
   410.90 
Abnormal mammogram unspecified ü    793.80 
Unspecified nonpsychotic mental disorder ü    300.9 
Acute apical periodontitis of pulpal origin ü    522.4 
Poisoning by other specified drugs and medicinal 
substances ü 
   977.8 
Personal history of other malignant neoplasm of skin ü    V10. 83 
Mitral valve insufficiency and aortic valve stenosis ü    396.2 
Reflex sympathetic dystrophy of the upper limb ü    337.21 
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Features 
 
Logistic 
Regression 
 
Decision 
Tree 
 
Gradient 
Boosting 
 
Random 
Forest 
 
ICD-9 
Codes 
Other and unspecified alcohol dependence   ü ü 303.90 
Generalized anxiety disorder   ü ü 300.02 
Unspecified viral hepatitis c without hepatic coma   ü ü 070.70 
Posttraumatic stress disorder   ü  309.81 
Cellulitis and abscess of upper arm and forearm   ü  682.3 
Senile nuclear sclerosis   ü  366.16 
Routine infant or child health check   ü ü V20. 2 
Depressive disorder not elsewhere classified    ü 311 
Other alteration of consciousness    ü 780.09 
Encounter for therapeutic drug monitoring    ü V58. 83 
Chronic hepatitis c without mention of hepatic coma    ü 070.54 
Laboratory examination unspecified    ü V72. 62 
Tobacco use disorder    ü 305.1 
Examination of eyes and vision    ü V72. 0 
 
 Table 4 
Performance of the Random Forest model on the test dataset after RFE and 
excluding features related to prior history of opioid dependency and abuse  
Step Class Precision Recall F-1 score AUC 
Including opioid 
dependency features 
NOUD 1 0.98 0.99 
0.97 
OUD 0.46 0.97 0.62 
Excluding opioid 
dependency features 
NOUD 1 0.95 0.97 0.83 OUD 0.19 0.72 0.3 
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Table 5 
List of diagnoses used to determine opioid use disorder 
Description of diagnoses used to determine opioid use disorder ICD-9 codes 
Opioid type dependence unspecified 304.00 
Opioid type dependence continuous 304.01 
Opioid type dependence episodic 304.02 
Opioid type dependence in remission 304.03 
Combinations of opioid type drug with any other drug dependence unspecified 304.70 
Combinations of opioid type drug with any other drug dependence continuous 304.71 
Combinations of opioid type drug with any other drug dependence episodic 304.72 
Combinations of opioid type drug with any other drug dependence in remission 304.73 
Opioid abuse unspecified 305.50 
Opioid abuse unspecified 305.51 
Opioid abuse episodic 305.52 
Opioid abuse in remission 305.53 
Poisoning by opium (alkaloids) unspecified 965.00 
Poisoning by heroin 965.01 
Poisoning by methadone 965.02 
Poisoning by other opiates and related narcotics 965.09 
Accidental poisoning by heroin E850.0 
Accidental poisoning by other opiates and related narcotics E850.2 
Heroin causing adverse effects in therapeutic use E935.0 
Other opiates and related narcotics causing adverse effects in therapeutic use E935.2 
 
